Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M34.4Revenue $M0.2Net Margin (%)-1,800.0Z-Score2.5
Enterprise Value $M10.0EPS $-2.4Operating Margin %-1,816.8F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-1,800.0Higher ROA y-yY
Price/Book1.310-y EBITDA Growth Rate %-37.1Quick Ratio12.9Cash flow > EarningsY
Price/Sales76.85-y EBITDA Growth Rate %-65.7Current Ratio12.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-53.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-57.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M10.5ROI % (ttm)-70.6Gross Margin Increase y-yN

Gurus Latest Trades with ROSG

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

ROSG is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ROSG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about ROSG :

    Quarterly/Annual Reports about ROSG:

      News about ROSG:

      Articles On GuruFocus.com
      Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update Sep 08 2009 
      Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd. Jan 08 2009 
      Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

      More From Other Websites
      Nasdaq stocks posting largest volume increases Oct 17 2014
      Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells Oct 13 2014
      ROSG: Rosetta Genomics Reports Better Than Expected Financial Results for 1H2014 Sep 19 2014
      Half Year 2014 Rosetta Genomics Ltd Earnings Release - Time Not Supplied Sep 18 2014
      Rosetta Genomics Reports Financial Results for the First Half of 2014 Sep 17 2014
      Rosetta Genomics to Host Business Update Conference Call on September 18, 2014 Sep 10 2014
      Rosetta Genomics Initiates Post-Marketing Registry Study of Its Cancer Origin Test Sep 03 2014
      Rosetta Genomics to Participate in September Investor Conferences Sep 02 2014
      Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based... Sep 02 2014
      Rosetta Genomics Expands Management Team With Appointment of Douglas Sites as Executive Vice... Aug 18 2014
      Rosetta Genomics Announces Agreement With Global Pharmaceutical Company to Advance Efforts in... Jul 31 2014
      Rosetta Genomics Announces Next-Generation Sequencing Research Collaboration With Weizmann Institute... Jul 29 2014
      Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test Jul 22 2014
      Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer Jul 10 2014
      ROSG: Collaboration Accelerates Product Development and Represents New Avenue for Revenue Growth Jun 27 2014
      Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of... Jun 26 2014
      UPDATE: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of... Jun 09 2014
      Rosetta, Moffitt enter into agreement for thyroid neoplasia assay Jun 09 2014
      Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of... Jun 09 2014
      UPDATE: Barrington Research Initiates Coverage On Rosetta Genomics Ltd. On Good Market Position Jun 04 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK